Richard Pazdur will retire from the Meals and Drug Administration solely weeks after being named the top of its major drug evaluate workplace.
A spokesperson for the FDA confirmed that Pazdur, the director of the Heart for Drug Analysis and Analysis, has submitted paperwork to retire on the finish of December. The information was first reported by Stat Information.
“We respect Dr. Pazdur’s resolution to retire and honor his 26 years of distinguished service on the FDA,” the spokesperson wrote in an e mail to BioPharma Dive. “Because the founding director of the Oncology Heart of Excellence, he leaves a legacy of cross-center regulatory innovation that strengthened the company and superior look after numerous sufferers. His management, imaginative and prescient, and dedication will proceed to form the FDA for years to come back.”
Printed experiences have indicated Pazdur may nonetheless reverse his resolution. If not, nonetheless, his departure would add to what’s already been important turnover among the many management ranks of the nation’s high drug regulator.
For the reason that starting of the second Trump administration, a number of key officers have resigned amid mass layoffs and experiences of a poisonous setting. Vinay Prasad, a longtime critic of the company, was named the chief of the FDA workplace that evaluates vaccines and gene therapies in Might, give up two months later and shortly took the job once more. George Tidmarsh was employed to run CDER in July however resigned in November amid a probe into his conduct.
The company has, alongside the way in which, change into extra unpredictable to business watchers by way of regulatory critiques. Although the FDA has introduced a number of initiatives designed to velocity drug improvement, it’s additionally shifted its stance and stunned sure firms that believed their functions to be on monitor. Some Wall Road analysts have detected an uptick in delayed drug critiques. And the regulator has additionally drawn criticism for sure drug rejections in addition to a new kind of voucher program some lawmakers have likened to a instrument of “political favoritism.”
Pazdur’s appointment, although, was seen as a doubtlessly stabilizing power. He’s labored on the FDA since 1999 and was the founding director of the Oncology Heart of Excellence in 2017. On the company, he led a sequence of initiatives to streamline the approval of latest most cancers medicines, but additionally held agency on supportive proof and pushed for therapies to be withdrawn when essential.
Pazdur is “arguably essentially the most certified candidate in the complete healthcare ecosystem for this function,” wrote RBC Capital Markets analyst Brian Abrahams, when he was employed. “We additionally see a low probability of controversies or adverse headlines that in current months might have spooked some healthcare buyers.”
Since then, biotech shares have continued an prolonged rally. However in response to The Washington Put up, Pazdur has additionally expressed considerations about that very same voucher program in addition to different strikes the FDA has been making to speed up drug improvement.
That he’s now determined to presumably retire is a “important, sudden and stunning flip” that “raises considerations over the long run path” of CDER in addition to the FDA’s “capability to take care of its present tempo of progress,” RBC’s Abrahams wrote, in a brand new notice on Tuesday. Ought to Pazdur finally go away, the principle query for biotech is whether or not his successor will likely be somebody with important regulatory or business expertise, or an “out-of-the-box choice from the MAHA sphere.”
Total, “the departure of this well-respected chief provides uncertainty and is a internet adverse for many of the sector,” Abrahams wrote, including that “it could not be unreasonable” for Commissioner Martin Makary’s tenure to be “on shaky floor.”
